Clinical trial

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

NCT04124484

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-10-17

PhasePHASE2

Study timeline

Study start (actual)2017-10-17Date precision: day

Registry last updated2019-10-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)DRUG

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)DRUG

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)DRUG

Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)DRUG

Sponsors & collaborators

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04124484 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.